Intravitreal bevacizumab for postviral fever retinitis: a novel approach for early resolution of macular oedema.
Severe macular oedema causing marked loss of vision is seen in cases of retinitis developing postviral fever. The use of antivascular endothelial growth factor agents for macular oedema and submacular fluid secondary to viral retinitis has not been studied or well established in the past. We report a case series of two patients of postviral retinitis with severe macular oedema resistant to steroid therapy, treated with intravitreal bevacizumab. The patients showed significant symptomatic improvement in the visual acuity. The retinitis lesions resolved slowly and macular oedema regressed. Bevacizumab appears to be a safe and useful agent to manage macular oedema subsequent to postviral retinitis. An early resolution of macular oedema helps in the preservation of visual acuity which left untreated can cause severe visual loss.
['Chawla|Rohan|R|', 'Sundar|Dheepak M|DM|', 'Gupta|Prasad|P|', 'Mittal|Kanhaiya|K|']
D020533:Angiogenesis Inhibitors D000068258:Bevacizumab D005334:Fever D006801:Humans D058449:Intravitreal Injections D008269:Macular Edema D008297:Male D008875:Middle Aged D012173:Retinitis D016896:Treatment Outcome D055815:Young Adult
eye macula retina therapeutic indications